<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H2E3B35A4973B4EF791011942E90D5F55" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 2452 IH: To amend the Federal Food, Drug, and Cosmetic Act with respect to facilitating dissemination of health care economic information.</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-05-19</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>114th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 2452</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20150519">May 19, 2015</action-date>
			<action-desc><sponsor name-id="L000576">Mr. Long</sponsor> (for himself, <cosponsor name-id="S001180">Mr. Schrader</cosponsor>, and <cosponsor name-id="B001248">Mr. Burgess</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Federal Food, Drug, and Cosmetic Act with respect to facilitating dissemination of
			 health care economic information.</official-title>
	</form>
	<legis-body id="H0858FAA9FA164CC4BF8FC4EB7E9D2235" style="OLC">
 <section commented="no" display-inline="no-display-inline" id="H34DF8D2CFA6040CFA220B76EBAF8DE1B" section-type="section-one"><enum>1.</enum><header>Facilitating dissemination of health care economic information</header><text display-inline="no-display-inline">Section 502(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/352">21 U.S.C. 352(a)</external-xref>) is amendedâ€”</text> <paragraph commented="no" id="H7B1F432F0D334143B22B3264BD0FCC55"><enum>(1)</enum><text>by striking <quote>(a) If its</quote> and inserting <quote>(a)(1) If its</quote>;</text>
 </paragraph><paragraph commented="no" id="HDBA1231ACEE54D078A5F53BEFE739F2A"><enum>(2)</enum><text display-inline="yes-display-inline">by striking <quote>a formulary committee, or other similar entity, in the course of the committee or the entity carrying out its responsibilities for the selection of drugs for managed care or other similar organizations</quote> and inserting <quote>a payor, formulary committee, or other similar entity with knowledge and expertise in the area of health care economic analysis, carrying out its responsibilities for the selection of drugs for coverage or reimbursement</quote>;</text>
 </paragraph><paragraph commented="no" id="H35200A5FFE4A49E5AF535065D3E8CD18"><enum>(3)</enum><text>by striking <quote>directly relates</quote> and inserting <quote>relates</quote>;</text> </paragraph><paragraph commented="no" id="HA619861F806B43EFBD0C321F1F10F513"><enum>(4)</enum><text display-inline="yes-display-inline">by striking <quote>and is based on competent and reliable scientific evidence. The requirements set forth in section 505(a) or in section 351(a) of the Public Health Service Act shall not apply to health care economic information provided to such a committee or entity in accordance with this paragraph</quote> and inserting <quote>, is based on competent and reliable scientific evidence, and includes, where applicable, a conspicuous and prominent statement describing any material differences between the health care economic information and the labeling approved for the drug under section 505 or under section 351 of the Public Health Service Act. The requirements set forth in section 505(a) or in subsections (a) and (k) of section 351 of the Public Health Service Act shall not apply to health care economic information provided to such a payor, committee, or entity in accordance with this paragraph</quote>; and</text>
 </paragraph><paragraph commented="no" id="HCCEDF3D0A2BC4083BF18849415352C88"><enum>(5)</enum><text>by striking <quote>In this paragraph, the term</quote> and all that follows and inserting the following:</text> <quoted-block display-inline="no-display-inline" id="HA624CBE8840A4970831743BE1F8180A1" style="OLC"> <paragraph commented="no" id="H0415B8F1B5664B43B06B94AF66DDF148" indent="up1"><enum>(2)</enum> <subparagraph commented="no" display-inline="yes-display-inline" id="H2EC5BAAAD60D427CACC4DFC3145BCA7B"><enum>(A)</enum><text>For purposes of this paragraph, the term <quote>health care economic information</quote> means any analysis (including the clinical data, inputs, clinical or other assumptions, methods, results, and other components underlying or comprising the analysis) that identifies, measures, or describes the economic consequences, which may be based on the separate or aggregated clinical consequences of the represented health outcomes, of the use of a drug. Such analyses may be comparative to the use of another drug, to another health care intervention, or to no intervention.</text>
 </subparagraph><subparagraph id="HD97DF9102CCA4856A8742922CB650F8E" indent="up1"><enum>(B)</enum><text display-inline="yes-display-inline">Such term does not include any analysis that relates only to an indication that is not approved under section 505 or under section 351 of the Public Health Service Act for such drug.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
			</paragraph></section></legis-body>
</bill>


